Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2024 · 10-Q
Revenue$284.00K$284.00K−67.7% vs Q1 2023 Net Income-$18.31M-$18.31MN/M vs Q1 2023 EPS Diluted-$0.02-$0.02N/M vs Q1 2023 Operating Income-$15,744,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,645,000— Margins · derivedOperating margin-5543.7%−4070.5 pt vs Q1 2023
Net margin-6447.9%−5237.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 10, 2024 · 40 d after period end